a cost-efficient GWAS array with additional clinically-relevant content (see https://www.illumina.com/content/dam/illuminamarketing/documents/products/datasheets/infinium-commercial-gsa-data-sheet-370-2016-016.pdf). The Affymetrix UK Biobank array is optimized for "populations of European and British ancestry" and indeed was initially designed for use in the UK Biobank (see http://www.affymetrix.com/support/technical/datasheets/uk_axiom_biobank_genotyping_arrays_ datasheet.pdf). The Illumina HumanCore, OmniExpress, Omni2.5M and Omni5M are included as earlier-generation arrays to serve as reference points for coverage.
II.
Materials and Methods For these genomic coverage assessments, we used the publicly available 1000 Genomes Project Phase 3 integrated variant set, in variant call format (VCF, available at http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/). Samples are grouped into continental panels or "super-populations" 5 : African (AFR), Americas (AMR), East Asian (EAS), European (EUR), and South Asian (SAS) -see Table 1 . Following our published methods 7 , we first randomly assigned each of the 2,504 Phase 3 samples into one of ten batches, balancing samples across populations. We then created subsets of the data in the 1000 Genomes VCF files, which are separated by chromosome. For each sample batch, we extracted genotypes from the VCF files for just the samples in the batch and the variants on the array. Array variants were identified within the VCF using chromosome and base pair positions from the most current array manifests available from vendor websites (see Table 2 ). A graphical overview of our methods is shown in Figure 1 .
We removed the VCF phasing information when converting to PLINK binary format (via VCFtools 8 ) to better approximate array genotypes, which are usually at first unphased. We then used SHAPEIT2 9 (v2.r790) software to pre-phase each dataset. The resulting phased haplotypes were then imputed with IMPUTE2 10 (v2. 3.2) where, for each batch, the remaining 1000 Genomes samples served as a worldwide imputation reference panel. We restricted imputation to variants with at least two copies of the minor allele in any one of the five super-populations. Following imputation, the output (genotype probabilities file) for each of the ten sample batches was then combined. We restricted these experiments to chromosomes 1 and 22.
To assess imputation accuracy and by extension genomic coverage, we compared imputed results at all the non-array variants to observed genotypes from the original VCF files. This comparison was performed separately by super-population and restricted to variants with at least two copies of the minor allele in the given panel, yielding 2,701,990 variants in the AFR panel; 1,709,647 in AMR; 1,304,742 in EAS; 1,401,215 in EUR; and 1,556,550 in SAS (note counts are across chromosomes 1 and 22). This variant restriction was done to avoid an excess of missing imputation metrics, which occur when a variant is either imputed or observed to be monomorphic. Imputation included all three variant types in the 1000 Genomes Project release: single nucleotide, insertion/deletion, and structural variants, and thus all three variant types were included in these metrics calculations.
For each variant we calculated three metrics: (1) the squared correlation between observed and imputed allelic dosage, which we call "dosage r 2 "; (2) the concordance between observed and most likely imputed genotype, the "genotype concordance"; and (3) the concordance between observed and most likely imputed genotype, when at least one of those two genotypes contains one or two copies of the minor allele, which we call "minor allele (MA) concordance." All metrics were calculated using R statistical and graphing software 11 . Array (observed) variants are included in these metrics summaries and are given dosage r 2 , genotype concordance, and MA concordance values of 1.
III.
Results and Discussion Figure 2 shows the fraction of variants passing a dosage r 2 threshold of 0.8. Each quadrant represents a different minor allele frequency (MAF) bin, where MAF was calculated in each superpopulation. Genomic coverage assessments commonly use the MAF groupings of >1% and >5%, which we have shown in panels C and D, respectively. The position of arrays along the x-axis indicates the total number of unique positions assayed by each array. Thus the least dense array is to the far left (Illumina HumanCore) and the densest array to the far right (Illumina Omni5M). Figure 3 shows mean MA concordance, by MAF bin and super-population. Similarly Figure 4 shows mean dosage r 2 , and Figure 5 shows genotype concordance. All the data plotted in Figures 2 -5 are presented numerically in Tables 3A-E, which also include tabular summaries of mean dosage r 2 and genotype concordance. Tables 3A-E also indicate the counts of variants in each MAF bin, as this count differs by super-population. The same metrics are also presented in barplots in Appendix A, for an alternative visualization.
As one might expect, quality metrics generally improve with increasing array density, regardless of either super-population or MAF bin. Rare variants (MAF < 1%) are generally not well imputed by either low or high density arrays. Common (MAF> 5%) variants are generally well imputed by all arrays, though there is still a distinction between the sparsest and densest arrays. Most of the line plots are monotonic. Some notable exceptions are the transitions between (1) OmniExpress and Affy UK Biobank in the AFR super-population and between (2) Affy UK Biobank and the Multi-Ethnic arrays in the EUR super-population.
The Multi-Ethnic global array and sub-arrays each assay a similar number of variants, though the global array has a slightly higher density. According to product literature, the Multi-Ethnic AMR/AFR array ("ME_amr" in plots) is designed for use in Hispanic and African American populations, while the Multi-Ethnic EUR/EAS/SAS array ("ME_eur" in plots) is designed for use in European, East Asian, and South Asian populations. Notably, according to these experiments, the Multi-Ethnic AMR/AFR array does not consistently outperform Multi-Ethnic EUR/EAS/SAS array for the AFR and AMR 1000 Genomes panels. However, this may be because populations in AMR and AFR are imperfect proxies for contemporary Hispanic and African American populations in the US. In contrast, for EUR, EAS, and SAS panels, the Multi-Ethnic EUR/EAS/SAS does perform slightly better than Multi-Ethnic AMR/AFR, which is consistent with the stated purpose of the arrays. While denser, the Multi-Ethnic global array does not consistently outperform the subarrays, though the relative performances vary by super-population and MAF bin.
The GSA results are generally consistent with what one would expect based on array densities: coverage is better than the less dense HumanCore but not as good as for the OmniExpress, the next densest assessed array after the GSA. One situation in which GSA outperforms the OmniExpress is for MAF 1-5% variants in the EUR and, to a lesser extent, the EAS super-populations. Notably, in contrast to the mostly tagging-focused OmniExpress, the GSA devotes ~10% of its content to clinically-relevant markers. These clinically-relevant markers may be underperforming as an imputation basis but derive value from their clinical associations. There are several potential limitations to these analyses. First, by assessing genomic coverage in the context of genome-wide imputation, we can only assess array variants that are also present in the chosen reference panel (1000 Genomes Phase 3 integrated variant set). Thus not all array variants can inform the imputation, for one of two reasons: (1) the array variant is not present in this 1000 Genomes Project dataset or (2) the array variant is present but without two or more copies of the minor allele in any one of the five super-populations (the MAF filtering threshold for imputation). In Table 2 we show for each array the percent overlap with 1000 Genomes at any allele frequency and the percent overlap with the 1000 Genomes with the requisite minor allele count to be included in imputation. Notably, the Multi-Ethnic arrays have less overlap than the other arrays.
A second caveat is that we used chromosomes 1 and 22 to estimate genome-wide coverage. Above we present coverage for the two chromosomes combined. To assess whether coverage patterns were consistent across these two chromosomes, we also evaluated them separately. We observed a statistically significant different between the two chromosomes for all four coverage metrics. However, the trends in coverage for the two chromosomes are quite consistent across arrays, for each of the super-populations and MAF bins. These patterns are illustrated in Figure 6 . While the absolute coverage metrics may differ, the relative coverage is similar -evidence that supports the reliability of our approach here. Furthermore, it is not surprising that coverage may differ by chromosome, given that chromosomes are heterogeneous with respect to structure, gene density, and CG content 12 . This heterogeneity of features may lead to differential destiny of genotyping assays on a SNP array and thus differences in coverage across chromosomes. Other factors, such as LD patterns, may also vary among chromosomes. Our primary goal here is to get a sense of how arrays compare to each other and to observe the trade-offs in assay density and genomic coverage. (Note GSA is absent from these chromosome-specific analyses, due to timing of coverage experiments. However, given the consistency of the chromosome-specific trends across the remaining arrays, it is reasonable to expect the same trends would hold for GSA.)
In summary, our current and previous 7 imputation-based genomic coverage analyses are intended to help researchers weigh the costs and benefits of different array choices across different genetic ancestry groups. Ultimately, the genomic coverage afforded by a given array will likely be affected by many study-specific factors, such as genotyping quality, genetic ancestry profile of study samples, and imputation procedures. These findings, however, can serve as a robust starting point for researchers evaluating their genotyping array options. Table 1 . An overview of the 2,504 samples in the 1000 Genomes Project Phase 3 reference used for these coverage assessments. The Project assigned each population to one of five super-populations: African (AFR), Americas (AMR), East Asian (EAS), European (EUR), and South Asian (SAS). Each sample was assigned to one of ten test batches at random, yet keeping an even representation of populations across batches. [1] [2] [3] [4] [5] [6] [7] [8] [9] ; batch 10 took the remainder, and thus each population contributed slightly more or fewer samples.
Full Population Name
7 Table 2 . Summaries of each array included in these genomic coverage analyses. "Product information" refers to the manifest version; "Date manufactured" and "Loci Count" were extracted from the array manifest headers. The last two columns indicate the percentage of unique positions assayed by the array (mapped to chromosomes 1 through 22 and the non-pseudoautosomal portion of the X chromosome) that are also found in the 1000 Genomes Phase 3 ("1000G Ph3") integrated variant set. The second to last column is over all 1000 Genomes variants while the last column is restricted to those with a minimum of two minor allele copies seen in at least one of the five super-populations. Because the last column is over a restricted set of 1000 Genomes variants, the percentage overlap decreases. Note coverage analyses were restricted to chromosomes 1 and 22. Arrays are manufactured by Illumina, with the exception of the Affymetrix UK Biobank. Tables 3A-3E . Genome-wide coverage estimates for all evaluated arrays, separately by MAF bin and super-population. "Number of variants" gives the count of 1000 Genomes Phase 3 variants per MAF bin for the given super-population. This count includes "observed" (i.e., included on the assessed array) variants, which have dosage r 2 and concordance values of 1. The "geno conc" is the genotype concordance; "MA conc" is the minor allele concordance (see narrative for details). Each plot in the grid is for a given MAF group (as rows) and super-population (as columns). The bars show the difference in fraction of variants with r 2 > 0.8, subtracting the value for the array indicated from the Multi-Ethnic global array. Note the Multi-Ethnic global array is omitted from the plot, as the comparison is always 0% difference. Positive values on the x-axis mean Multi-Ethnic global has higher coverage; negative values means the labelled array has higher coverage. The Global Screening Array was not assessed for chromosomespecific metrics and is thus not represented on this plot.
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